Metricure (Canada)
This treatment applies to the following species:
CEPHAPIRIN BENZATHINE UTERINE SUSPENSION
FOR VETERINARY USE ONLY
Sterile
DIN 02237680
DESCRIPTION
Each 19 gram syringe contains:
ACTIVE INGREDIENTS:
640 mg cephapirin benzathine
NON-MEDICINAL INGREDIENTS:
0.09 g cetomacrogol 1000 (emulsifier)
0.21 g eumulgin B1 (emulsifier)
0.15 g hydrogenated castor oil (stabilizer)
in fractionated coconut oil (vehicle)
THERAPEUTIC CLASSIFICATION
Antibiotic.
INDICATIONS
Metricure is an antibiotic indicated for the treatment of subacute and chronic endometritis in cows caused by Actinomyces (Corynebacterium) pyogenes, Fusobacterium necrophorum and pigment-forming Bacteroides strains.
To accurately diagnose subacute or chronic endometritis, a vaginoscopic examination should be done to confirm the presence of a discharge from the cervix.
DOSAGE AND ADMINISTRATION
Thoroughly clean the vulvar area, maintain aseptic conditions and avoid contaminating the catheter in preparation for the infusion.
Introduce a single dose of 640 mg of cephapirin benzathine (one 19 g syringe) into the lumen of the uterus using a disposable catheter. Fix the syringe to the catheter, then taking the cervix into a gloved hand introduced into the rectum; introduce the catheter through the cervix into the lumen of the uterus by gentle oscillating movements of the cervix. Inject the contents of the syringe.
One treatment is usually sufficient for a complete cure. If the quantity and quality of the cervical discharge is not improved at examination 14 days after treatment, the cow should receive a second treatment. Other contaminating organisms not sensitive to cephapirin may be the cause of the infection and accurate laboratory diagnosis may be necessary. In inseminated animals, Metricure can be used one day following insemination.
Note
Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.
CAUTIONS
In case of anaphylactic reaction administer epinephrine.
WARNINGS
Treated animals must not be slaughtered for use in food for at least 48 hours after the latest treatment with this drug.
No milk withholding time is required when used according to the label.
Cephalosporins can cause allergic reactions in sensitized individuals. When handling the product, avoid oral exposure and direct contact with skin or eyes.
Keep out of reach of children.
ADVERSE REACTIONS
Allergic reactions have been observed in very rare cases.
PHARMACOLOGY
Cephapirin, a first generation cephalosporin, is a broad spectrum antibiotic with bactericidal action against sensitive gram-positive bacteria and gram-negative anaerobic bacteria. It is resistant to the action of penicillinase and is active in an anaerobic environment as encountered in an infected uterus. After a single treatment with Metricure, concentrations of cephapirin in endometrial tissue above the MIC of sensitive bacteria are maintained for at least 24 hours.
The suspension is easily infused and is well tolerated, enabling good diffusion of cephapirin into the endometrium.
STORAGE
Store in a dry place between 15° and 25°C.
SUPPLY
Box of 10 x 19 g syringes, 10 catheters and 10 gloves.
Box of 12 x 19 g syringes.
Intervet Canada Corp, 16750, route Transcanadienne, Kirkland QC, H9H 4M7
1-866-683-7838
® Intervet International B.V. Used under license.
Intervet Canada Corp. is a subsidiary of Merck & Co., Inc.
Version 16 August 2017
CPN: 1208143.4
Intervet Canada Corp.
16750 ROUTE TRANSCANADIENNE, KIRKLAND, QC, H9H 4M7
Order Desk: | 514-428-7013 | |
Toll-Free: | 866-683-7838 | |
Fax: | Toll-free 888-498-4444; local 514-428-7014 | |
Website: | www.merck-animal-health.ca |
![]() |
THIS SERVICE AND DATA ARE PROVIDED "AS IS". Animalytix assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the Animalytix service and data. See the Terms of Use for further details. |
Copyright © 2025 Animalytix LLC. Updated: 2024-11-27